TREAT STUDY : TREATMENT OF IRON DEFICIENCY ANAEMIA WITH TARDYFERON. Importance of prolonging iron supplementation in anemic women of childbearing age - TREAT STUDY
Phase 1
- Conditions
- Iron Deficiency Anaemia is a common pathology which concerns less than 5% of women aged 15 to 49 years old in the western countries but can affect up to 30% of the world population, knowing that 9 to 10 anaemic patients live in developing countries. Treating at least 3 months allows to normalize haemoglobin but it is important to carry on the iron treatment in order to fully replenish the iron stores.
- Registration Number
- EUCTR2006-003378-90-FR
- Lead Sponsor
- PIERRE FABRE MEDICAMENT
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Ambulatory, menstruated female who have reached the legal majority in their country with mild to moderate iron deficiency anaemia
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
anaemia with haemoglobin level < 9g/dl or >11 g/dl
Normocytic or macrocytic anaemia
Normochromic or hyperchromic anaemia
Normosideremic or hypersideremic anaemia
Anaemia due to inflammatory disease, hemochromatosis, thalassemia, anaemia due to medullar insufficiency, refractory anaemia, chronic renal insufficiency
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method